News Image

Compugen Appoints David Silberman as Chief Financial Officer

Provided By PR Newswire

Last update: May 15, 2024

HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.

Read more at prnewswire.com

COMPUGEN LTD

NASDAQ:CGEN (7/25/2025, 8:00:00 PM)

After market: 1.54 +0.01 (+0.65%)

1.53

-0.01 (-0.65%)



Find more stocks in the Stock Screener

Follow ChartMill for more